Active — Not RecruitingNot Applicable

Application of in Vivo Splitting Technique in Adult Liver Transplantation

China500 participantsStarted 2021-01-01

Plain-language summary

The feasibility of split liver transplantation (SLT) remains controversial. This study aimed to evaluate the outcomes of SLT in adult recipients and to identify specific areas of improvements. A retrospective analysis was conducted on adults who underwent full size SLT between January 2021 and December 2023. The short-term outcomes of these patients who underwent SLT were compared with those of patients who underwent whole liver transplantation (WLT) during the same period.

Who can participate

Age range16 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. age of 18-60 years;
✓. BMI of 19-28 kg/m2;
✓. hemodynamic stability or use of a single vasoactive drug with a small dosage (norepinephrine ≤ 0.1 μg/kg/min or dopamine ≤ 5 μg/kg/min);
✓. liver steatosis ≤ 10%;
✓. liver functional indicators (ALT, AST, total bilirubin quantification) ≤ 3 times the normal value;
✓. blood sodium ≤ 160 mmol/L;
✓. Patients who had registered in the China Organ Transplant Response Systems.
✓. Initial liver transplantation.

Exclusion criteria

✕. uncontrollable infection
✕. significant vascular and biliary variation.
✕. Severe portal hypertension.
✕. Significant vascular variation.

What they're measuring

Overall survival

Timeframe: 2021.01.01-2025.12.31

Trial details

NCT IDNCT06925828

SponsorNingbo Medical Center Lihuili Hospital

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2025-12-31

View on ClinicalTrials.gov More Liver Transplantation trials